EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis
Por:
Zabotti, A, De Marco, G, Gosset, L, Baraliakos, X, Aletaha, D, Iagnocco, A, Gisondi, P, Balint, PV, Bertheussen, H, Boehncke, WH, Damjanov, NS, de Wit, M, Errichetti, E, Marzo-Ortega, H, Protopopov, M, Puig, L, Queiro, R, Ruscitti, P, Savage, L, Schett, G, Siebert, S, Stamm, TA, Studenic, P, Tinazzi, I, Van den Bosch, FE, van der Helm-van Mil, A, Watad, A, Smolen, JS, McGonagle, DG
Publicada:
9 jun 2023
Ahead of Print:
1 jun 2023
Resumen:
BackgroundThe transition from psoriasis (PsO) to psoriatic arthritis (PsA) and the early diagnosis of PsA is of considerable scientific and clinical interest for the prevention and interception of PsA. ObjectiveTo formulate EULAR points to consider (PtC) for the development of data-driven guidance and consensus for clinical trials and clinical practice in the field of prevention or interception of PsA and for clinical management of people with PsO at risk for PsA development. MethodsA multidisciplinary EULAR task force of 30 members from 13 European countries was established, and the EULAR standardised operating procedures for development for PtC were followed. Two systematic literature reviews were conducted to support the task force in formulating the PtC. Furthermore, the task force proposed nomenclature for the stages before PsA, through a nominal group process to be used in clinical trials. ResultsNomenclature for the stages preceding PsA onset, 5 overarching principles and 10 PtC were formulated. Nomenclature was proposed for three stages towards PsA development, namely people with PsO at higher risk of PsA, subclinical PsA and clinical PsA. The latter stage was defined as PsO and associated synovitis and it could be used as an outcome measure for clinical trials evaluating the transition from PsO to PsA. The overarching principles address the nature of PsA at its onset and underline the importance of collaboration of rheumatologists and dermatologists for strategies for prevention/interception of PsA. The 10 PtC highlight arthralgia and imaging abnormalities as key elements of subclinical PsA that can be used as potential short-term predictors of PsA development and useful items to design clinical trials for PsA interception. Traditional risk factors for PsA development (ie, PsO severity, obesity and nail involvement) may represent more long-term disease predictors and be less robust for short-term trials concerning the transition from PsO to PsA. ConclusionThese PtC are helpful to define the clinical and imaging features of people with PsO suspicious to progress to PsA. This information will be helpful for identification of those who could benefit from a therapeutic intervention to attenuate, delay or prevent PsA development.
Filiaciones:
Zabotti, A:
Azienda Sanit Univ Friuli Cent, Dept Med & Biol Sci, Udine, Italy
De Marco, G:
Chapel Allerton Hosp, Leeds Musculoskeletal Biomed Res Ctr, Leeds, England
Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England
Gosset, L:
Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, INSERM, Paris, France
Hop Univ Pitie Salpetriere, APHP, Rheumatol Dept, Paris, France
Baraliakos, X:
Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany
Aletaha, D:
Med Univ Vienna, Dept Rheumatol, Vienna, Austria
Iagnocco, A:
Univ Torino, Sci Clin & Biol, Turin, Italy
Gisondi, P:
Univ Verona, Sect Dermatol & Venereol, Dept Med, Verona, Italy
Balint, PV:
Natl Inst Rheumatism & Physiotherapy, Dept Rheumatol 3, Budapest, Hungary
Bertheussen, H:
Patient Res Partner, Oslo, Norway
Boehncke, WH:
Geneva Univ Hosp, Dermatol, Geneva, Switzerland
Damjanov, NS:
Univ Belgrade, Rheumatol, Fac Med, Beograd, Serbia
de Wit, M:
Univ Amsterdam, Med Humanities, Med Ctr, Duivendrecht, Netherlands
Errichetti, E:
Azienda Sanit Univ Friuli Cent, Univ Hosp Santa Maria della Misericordia, Dept Med & Biol Sci, Udine, Italy
Marzo-Ortega, H:
Chapel Allerton Hosp, Leeds Musculoskeletal Biomed Res Ctr, Leeds, England
Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England
Protopopov, M:
Charite Univ Med Berlin, Dept Gastroenterol Infectiol & Rheumatol, Campus Benjamin Franklin, Berlin, Germany
Puig, L:
Hosp Santa Creu & Sant Pau, Dermatol, Barcelona, Spain
Queiro, R:
Hosp Univ Cent Asturias, Rheumatol, Oviedo, Spain
Ruscitti, P:
Univ Laquila, Dept Clin Sci & Appl Biotechnol, Laquila, Italy
Savage, L:
Chapel Allerton Hosp, Dept Dermatol, Leeds, England
Schett, G:
Erlangen Univ Hosp, Rheumatol, Erlangen, Germany
Siebert, S:
Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Scotland
Stamm, TA:
Med Univ Vienna, Sect Outcomes Res, Vienna, Austria
Studenic, P:
Med Univ Vienna, Dept Rheumatol, Vienna, Austria
Tinazzi, I:
Don Calabria Sacred Heart Hosp, Unit Rheumatol, Negrar, Italy
Van den Bosch, FE:
Univ Ghent, Rheumatol, Ghent, Belgium
van der Helm-van Mil, A:
Leiden Univ, Med Ctr, Rheumatol, Leiden, Netherlands
Erasmus MC, Rheumatol, Rotterdam, Netherlands
Watad, A:
Sheba Med Ctr Tel Hashomer, Int Med, Tel Hashomer, Israel
Smolen, JS:
Med Univ Vienna, Dept Rheumatol, Vienna, Austria
McGonagle, DG:
Chapel Allerton Hosp, Leeds Musculoskeletal Biomed Res Ctr, Leeds, England
Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England
Bronze, All Open Access; Green
|